Objective： To observe the clinical effect of Qingre Jiedu prescription combined with interventional chemoembolization with lobaplatin for primary liver cancer. Methods：A total of 110 cases of patients with primary liver cancer were randomly divided into the observation group and the control group，55 cases in each group. The control group was given interventional chemoembolization with lobaplatin，and the observation group was additionally given Qingre Jiedu prescription based on the treatment of the control group. Both groups were treated for three courses，30 days being a course. The clinical effect was observed in the two groups. Before and after treatment， score of Functional Assessment of Cancer Therapy- General(FACT-G) as well as contents of total bilirubin(TBil)，alanine aminotransferase(ALT)，and aspartate aminotransferase (AST) in serum was recorded. During treatment， toxic reactions caused by chemotherapeutic medicines were carried out statistical analysis. Results：The total effective rate was 45.45% in the observation group，and 25.45% in the control group， the difference being significant(P＜0.05). Before treatment，when compared levels of TBil，ALT，and AST in serum between the two groups，there was no significance being found in the difference(P＞0.05). After treatment，levels of TBil，ALT，and AST in serum in the two groups were decreased when compared with those before treatment(P＜0.05)，and the three levels in the observation group were lower than those in the control group(P＜0.05). Before treatment，when compared scores of all dimensions in FACT- G between the two groups， there was no significance being found in the difference(P＞0.05). After treatment，the scores of FACT-G scale in the observation group had little change compared with those before treatment(P＞ 0.05)， but they were higher than those in the control group(P＜0.05).The body dimension score of FACT- G scale in the control group was lower than that before treatment(P＜0.05)， and the other scores had little change(P＞0.05). In the observation group，the curative effect of grading of toxic reactions including upper gastrointestinal reaction，white blood cell count， and platelet count was better than that in the control group(P＜0.05). Conclusion： For patients with primary liver cancer，the therapy of Qingre Jiedu prescription combined with interventional chemoembolization with lobaplatin can give full play to treatment advantages of integrated Chinese and western medicine therapy， improve the liver function， promote quality of life，and effectively relieve adverse reactions caused by chemotherapeutic medicines.